T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1276
Hormel Foods
HRL
$13.4B
| $20.8M | ﹤0.01% |
426,898
-24,154
| -5% | -$1.06M |
|
|
EVRI
1277
DELISTED
Everi Holdings
EVRI
| $20.7M | ﹤0.01% |
970,614
+48,071
| +5% | +$1.1M |
|
|
CMA
1278
DELISTED
Comerica
CMA
| $20.7M | ﹤0.01% |
237,993
-2,664
| -1% | -$229K |
|
1279
Essential Utilities
WTRG
$11.3B
| $20.6M | ﹤0.01% |
383,087
-1,782
| -0.5% | -$86.5K |
|
1280
Enanta Pharmaceuticals
ENTA
$393M
| $20.5M | ﹤0.01% |
274,317
+12,194
| +5% | +$957K |
|
1281
First American
FAF
$7.38B
| $20.5M | ﹤0.01% |
262,150
+2,243
| +0.9% | +$167K |
|
1282
Duolingo
DUOL
$6.3B
| $20.5M | ﹤0.01% |
192,812
+30,036
| +18% | +$4.14M |
|
1283
Hasbro
HAS
$13.4B
| $20.4M | ﹤0.01% |
200,405
-6,614
| -3% | -$635K |
|
1284
Stepan Co
SCL
$1.48B
| $20M | ﹤0.01% |
160,865
-11,573
| -7% | -$1.4M |
|
1285
Chemed
CHE
$7.02B
| $19.8M | ﹤0.01% |
37,352
-9,348
| -20% | -$4.49M |
|
|
FBRT
1286
Franklin BSP Realty Trust
FBRT
$669M
| $19.6M | ﹤0.01% |
+1,315,257
| New | +$21.2M |
|
1287
1stdibs.com
DIBS
$163M
| $19.6M | ﹤0.01% |
1,567,043
-1,094,326
| -41% | -$15.2M |
|
|
SWTX
1288
DELISTED
SpringWorks Therapeutics
SWTX
| $19.3M | ﹤0.01% |
312,041
+4,634
| +2% | +$307K |
|
1289
Huntington Ingalls Industries
HII
$12.9B
| $19.3M | ﹤0.01% |
103,485
-6,057
| -6% | -$1.17M |
|
1290
Rollins
ROL
$17.6B
| $19.2M | ﹤0.01% |
560,723
-8,724,392
| -94% | -$305M |
|
1291
Henry Schein
HSIC
$10.1B
| $19.2M | ﹤0.01% |
247,283
-9,150
| -4% | -$699K |
|
1292
Nkarta
NKTX
$171M
| $19.1M | ﹤0.01% |
1,246,396
+1,238,800
| +16,309% | +$21.2M |
|
1293
Pan American Silver
PAAS
$19.9B
| $19.1M | ﹤0.01% |
762,993
-33,524
| -4% | -$844K |
|
1294
BlackLine
BL
$1.82B
| $19M | ﹤0.01% |
183,773
-23,754
| -11% | -$2.75M |
|
1295
Jack Henry & Associates
JKHY
$10.8B
| $18.9M | ﹤0.01% |
113,142
-1,007,162
| -90% | -$163M |
|
1296
Bumble
BMBL
$344M
| $18.9M | ﹤0.01% |
557,775
+362,953
| +186% | +$15.4M |
|
1297
Ginkgo Bioworks
DNA
$486M
| $18.9M | ﹤0.01% |
56,734
+49,436
| +677% | +$23.5M |
|
1298
Aspen Aerogels
ASPN
$510M
| $18.7M | ﹤0.01% |
375,968
-76,862
| -17% | -$4.05M |
|
|
OSH
1299
DELISTED
Oak Street Health, Inc.
OSH
| $18.7M | ﹤0.01% |
563,762
-1,171,601
| -68% | -$44.3M |
|
1300
Sana Biotechnology
SANA
$1.1B
| $18.6M | ﹤0.01% |
1,204,696
+17,587
| +1% | +$339K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.